Business Context and Reporting Period
BioMarin Pharmaceutical Inc. is a biotechnology company focused on therapies for rare genetic disorders. This Form 10-K reports the fiscal year ended December 31, 2022; figures are annual, not standalone fourth-quarter results. Unless noted, amounts are in U.S. dollars.
Key developments included VOXZOGO’s global launch expansion and conditional EU approval of ROCTAVIAN for adults with severe hemophilia A. ROCTAVIAN had no product sales in 2022.
Financial and Operating Highlights
| Metric | 2022 | 2021 |
|---|---|---|
| Total revenue | $2.096 billion | $1.846 billion |
| Net product revenue | $2.042 billion | $1.783 billion |
| Gross margin | 76.9% | 74.5% |
| Operating income (loss) | $149.6 million | $(82.3) million |
| Net income (loss) | $141.6 million | $(64.1) million |
| Diluted EPS | $0.75 | $(0.35) |
| Cash from operating activities | $175.9 million | $304.5 million |
Revenue growth was led by VOXZOGO ($169.1 million versus $5.9 million), NAGLAZYME ($443.8 million), VIMIZIM ($663.8 million) and BRINEURA ($154.3 million). KUVAN revenue fell to $227.6 million from $285.8 million, primarily due to generic competition. Total revenue includes $54.0 million of royalty and other revenue.
Cash, cash equivalents and investments totaled $1.625 billion at year-end, up from $1.522 billion. Current assets were $2.751 billion and current liabilities $588.9 million. Convertible debt was $1.1 billion in undiscounted principal: $495 million due August 2024 and $600 million due May 2027. The $200 million revolving credit facility had no borrowings outstanding. Management said available cash, investments and expected product cash flows should meet liquidity needs for at least 12 months.
Research and development expense was $649.6 million, up from $628.8 million; selling, general and administrative expense was $854.0 million, up from $759.4 million. The filing does not provide a standalone fourth-quarter financial result in the supplied text.
Material Changes Versus the Prior Year
- Total revenue increased 13.5%, while net product revenue increased $258.5 million, driven mainly by VOXZOGO growth and higher NAGLAZYME, VIMIZIM and BRINEURA sales.
- Gross margin improved 2.4 percentage points, attributed to lower per-unit manufacturing costs, lower inventory reserves and a more favorable sales mix.
- Operating results moved from a loss to income. Results included a $108.0 million net gain on sale of the VOXZOGO priority review voucher; the gross proceeds were $110.0 million.
- Operating cash flow declined $128.6 million, mainly due to customer-receipt timing and the absence of a tax refund received in 2021.
- Foreign exchange reduced 2022 product sales by an estimated $59.0 million, compared with a $2.3 million favorable impact in 2021.
Outlook, Risks and Unusual Items
Management expects 2023 net product revenue growth across new and existing products other than KUVAN, whose sales face continued loss of exclusivity. It expects gross margin of 77.5%–79% over the following 12 months, and higher R&D and SG&A expense than in 2022. No numerical revenue or earnings guidance is provided in the supplied text.
- ROCTAVIAN’s FDA resubmission was under review, with a March 31, 2023 target action date and a possible three-month extension. Its EU authorization is conditional; launch uptake, payer access, durability of effect and potential outcomes-based repayments remain important uncertainties.
- VOXZOGO applications to expand treatment to younger children were under review; management expected U.S. and EU action in the second half of 2023.
- Pricing, reimbursement, generic competition (particularly for KUVAN), foreign exchange, variable government-order timing, and customer concentration are material commercial risks. Three customers generated 37% of 2022 net product revenue.
- Manufacturing depends partly on third parties and certain single-source suppliers. Gene therapy programs also carry additional clinical, regulatory, manufacturing, durability and reimbursement risks.
- The October 2022 reorganization reduced planned headcount by about 120 employees (approximately 4% of the workforce) and generated $23.0 million of 2022 severance and termination-benefit expense.
- Reasonably possible contingent payments totaled $762.5 million, including significant potential obligations tied to early-stage licensed programs. Purchase obligations were $225.5 million, of which $188.7 million was expected in 2023.
- The company disclosed shareholder litigation related to ROCTAVIAN and BMN 307, as well as a derivative action. It recorded a $13.0 million long-term loss contingency and an equal insurance recovery; outcomes remain uncertain.
The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting. The company corrected an immaterial prior-period error related to the FIRDAPSE rights sale; the correction reduced 2020 net income by $5.1 million.
Important Facts for Investors to Verify
- Whether ROCTAVIAN obtained U.S. approval and how payer agreements, patient eligibility, uptake and outcomes affect realized revenue and refund exposure.
- VOXZOGO’s growth, reimbursement expansion and regulatory decisions for younger age groups.
- KUVAN’s revenue trajectory under ongoing generic competition, and whether growth in other products offsets the decline.
- Cash generation and cash conversion, including the drivers of lower operating cash flow and inventory growth.
- Funding and repayment plans for the $495 million 2024 Notes, alongside investment and contingent-payment requirements.
- Progress and financial exposure from litigation, contingent obligations, manufacturing dependencies and foreign-exchange movements.